

**Regd. Office and works:**

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231  
Pithampur - 454775, Dist. Dhar  
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com)Website:- [www.medicaps.com](http://www.medicaps.com)**MCL/SE/2022-2023****Date: 09<sup>th</sup> February, 2023****Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)**

To,  
The General Manager  
DCS-CRD  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street Fort, Mumbai – 400001 (M.H.)

**Subject: Submission of the Standalone and Consolidated Un-audited Financial Results for the Quarter and Nine Months ended on 31<sup>st</sup> December, 2022 in terms of Regulation 33 of SEBI (LODR) Regulations, 2015.**

**Ref: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)**

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2022-2023 dated 01<sup>st</sup> February, 2023 regarding information of Board Meeting for consideration and approval of Standalone as well as Consolidated Un-Audited Financial Results for the Quarter and Nine months ended on 31<sup>st</sup> December, 2022.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2022 duly approved by the Board at its meeting held today i.e.09<sup>th</sup> February, 2023 along with Limited Review Report given by the Statutory Auditors of the Company, as required under the above said Regulations.

Further, copy of Un-Audited Financial Results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be uploaded on the Company's website [www.medicaps.com](http://www.medicaps.com) and on the website of the Stock Exchange at [www.bseindia.com](http://www.bseindia.com). Further the extracts of aforesaid results will be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Results for your records and reference.

Thanking You,  
Yours Faithfully,  
**FOR, MEDI-CAPS LIMITED**

**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**

*Encl.: Unaudited Standalone and Consolidated Financial Results along with limited review report for quarter and nine months ended 31<sup>st</sup> December, 2022;*

---

*Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,  
Opposite UCO Bank Indore (M.P.) 452001  
Contact No: 0731-4028148*

# RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380


E-mail : rawkaassociates@gmail.com, cpawka@gmail.com

**Independent Auditors' Review Report on Standalone Unaudited Quarterly and year to date Financial Results of Medi-Caps Limited ('the Company') pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,

THE BOARD OF DIRECTORS OF  
MEDI-CAPS LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter and Nine months ended December 31, 2022 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the Listing Regulations.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Date: 09.02.2023**


**Place: Indore**

**UDIN: 23429040BGXBCS7528**

**For, Rawka & Associates**

**(Chartered Accountants)**

**FRN 021606C**



A handwritten signature in black ink, appearing to read "Venus Rawka".

**Venus Rawka**  
**(Partner)**

**M. No. 429040**

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2022**

		(Amount in Lakhs except EPS)					
S.N.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		3 Month Ended 31/12/2022	Preceeding 3 Month Ended 30/09/2022	Corresponding 3 months ended in the previous year 31/12/2021	Year to date figures for current period ended 31/12/2022	Year to date figures for the previous year ended 31/12/2021	Previous Year ended March 31 2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I</b>	<b>Revenue from Operation</b>						
	(a) Net sales	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Other operating income	1.27	1.29	0.00	3.92	0.02	0.00
	<b>Revenue from Operation</b>	<b>1.27</b>	<b>1.29</b>	<b>0.00</b>	<b>3.92</b>	<b>0.02</b>	<b>0.00</b>
<b>II</b>	<b>Other Income</b>	0.09	60.52	43.50	61.87	46.41	60.74
<b>III</b>	<b>Total income (I+II)</b>	<b>1.36</b>	<b>61.81</b>	<b>43.50</b>	<b>65.79</b>	<b>46.43</b>	<b>60.74</b>
<b>IV</b>	<b>Expenses</b>						
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expense	6.03	6.11	31.68	17.56	40.55	45.13
	e) Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	2.31	2.30	5.44	6.92	16.31	9.23
	g) Power Cost	0.19	0.00	0.00	0.19	0.00	0.00
	h) Freight Exp.	0.00	0.00	0.00	0.00	0.00	0.00
	i) Other expenses	2.89	3.07	3.46	12.54	9.85	12.46
	<b>Total Expenses (IV)</b>	<b>11.42</b>	<b>11.50</b>	<b>40.58</b>	<b>37.21</b>	<b>66.71</b>	<b>66.82</b>
<b>V</b>	<b>Profit / (Loss) before exceptional item &amp; tax (III-IV)</b>	<b>-10.06</b>	<b>50.31</b>	<b>2.92</b>	<b>28.58</b>	<b>-20.28</b>	<b>(6.08)</b>
<b>VI</b>	<b>Exceptional items</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>VII</b>	<b>Profit/(Loss) before tax (V-VI)</b>	<b>-10.06</b>	<b>50.31</b>	<b>2.92</b>	<b>28.58</b>	<b>-20.28</b>	<b>(6.08)</b>
<b>VIII</b>	<b>Tax expense</b>						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00	0.00
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	1.44
	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>1.44</b>
<b>IX</b>	<b>Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>X</b>	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-10.06</b>	<b>50.31</b>	<b>2.92</b>	<b>28.58</b>	<b>-20.28</b>	<b>(7.52)</b>
<b>XI</b>	<b>Profit/(loss) from discontinued operations</b>	-3.98	-1.42	-3.22	-9.71	-0.42	3.72
<b>XII</b>	<b>Tax expense of discontinued operations</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>XIII</b>	<b>Profit/(loss) from Discontinued operations (after tax) (XI-XII)</b>	<b>(3.98)</b>	<b>(1.42)</b>	<b>(3.22)</b>	<b>(9.71)</b>	<b>(0.42)</b>	<b>3.72</b>
<b>XIV</b>	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>XV</b>	<b>Profit/(loss) for the period (X+XIII)</b>	<b>(14.04)</b>	<b>48.90</b>	<b>(0.30)</b>	<b>18.87</b>	<b>(20.70)</b>	<b>(3.80)</b>
<b>XVI</b>	<b>Other comprehensive income</b>						
	(a) (i) items that will not be reclassified to statement of profit & loss	19.25	-26.09	(35.94)	-31.32	29.25	35.69
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00

	(ii) Income tax on items that will be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Other comprehensive income :</b>	<b>19.25</b>	<b>-26.09</b>	<b>-35.94</b>	<b>-31.32</b>	<b>29.25</b>	<b>35.69</b>
<b>XVII</b>	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period	<b>5.21</b>	<b>22.81</b>	<b>(36.24)</b>	<b>-12.45</b>	<b>8.55</b>	<b>31.89</b>
<b>XVIII</b>	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	0.00
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
<b>XIX</b>	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
<b>XX</b>	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
<b>XXII</b>	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	-0.08	0.40	0.02	0.23	-0.16	(0.06)
	b) Diluted (Rs.)	-0.08	0.40	0.02	0.23	-0.16	(0.06)
	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	-0.03	(0.01)	(0.03)	(0.08)	0.00	0.03
	b) Diluted (Rs.)	-0.03	(0.01)	(0.03)	(0.08)	0.00	0.03
	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	-0.11	0.39	(0.01)	0.15	-0.16	(0.03)
	b) Diluted (Rs.)	-0.11	0.39	(0.01)	0.15	-0.16	(0.03)

DATE: 09.02.2023  
PLACE: INDORE



For and behalf of board of directors of  
MEDI-CAPS LIMITED

*(Signature)*  
**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

# RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS  
412, Arcade Silver 56, 1, New Palasia, Indore - 1  
☎ Off. : 2541132, Mobile : 9039080380  
E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

**Independent Auditor's Review Report On Consolidated Unaudited Quarterly and year to date Financial Results of Medi-Caps Limited (the Parent Company) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
THE BOARD OF DIRECTORS OF  
MEDI-CAPS LIMITED

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter and Nine month ended December 31, 2022, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), including relevant circular issued by the SEBI time to time.
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly owned subsidiary Medgel Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the financial results of Medgel Private Limited (wholly owned subsidiary) which also have been reviewed by us and certified by the management, whose interim consolidated financial results reflect total income of Rs.1120.77 Lakhs, total net loss after tax of Rs. (129.78) Lakhs and total comprehensive income of Rs. (80.60) Lakhs for the quarter ended December 31, 2022, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of above matter.

**Date: 09.02.2023**


**Place: Indore**

**UDIN: 23429040BGXBCT9148**

**For: Rawka & Associates**

(Chartered Accountants)

FRN: 021606C



**Venus Rawka**

(Partner)

M.No. 429040

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2022**

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		3 Month Ended 31/12/2022	Preceeding 3 Month Ended 30/09/2022	Corresponding 3 months ended in the previous year 31/12/2021	Year to date figures for current period ended 31/12/2022	Year to date figures for the previous year ended 31/12/2021	Previous Year ended March 31 2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I</b>	<b>Revenue from Operation</b>						
	(a) Net sales	1093.33	1528.81	1731.26	3839.38	5171.61	6831.10
	(b) Other operating income	10.51	8.49	47.04	40.80	60.14	156.01
	<b>Revenue from Operation</b>	<b>1103.84</b>	<b>1537.29</b>	<b>1778.30</b>	<b>3880.18</b>	<b>5231.75</b>	<b>6987.11</b>
<b>II</b>	<b>Other Income</b>	16.93	89.84	21.38	136.50	46.83	191.42
<b>III</b>	<b>Total income (I+II)</b>	<b>1120.77</b>	<b>1627.13</b>	<b>1799.68</b>	<b>4016.68</b>	<b>5278.58</b>	<b>7178.53</b>
<b>IV</b>	<b>Expenses</b>						
	a) Cost of material consumed	411.23	765.43	778.86	1720.43	2270.43	3004.63
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods work-in-progress and stock-in-trade	123.84	3.03	4.94	196.44	88.12	6.43
	d) Employee benefits expense	190.28	189.50	196.81	547.40	552.57	771.01
	e) Finance costs	0.02	0.01	0.02	0.15	0.02	0.02
	f) Depreciation and amortisation expense	50.25	51.75	47.34	152.26	142.02	181.32
	g) Power Cost	36.81	72.94	106.00	154.69	245.62	328.63
	h) Freight Exp.	67.34	158.86	311.93	394.77	640.36	1163.33
	i) Other expenses	107.20	169.93	145.63	437.89	480.57	717.40
	<b>Total Expenses (IV)</b>	<b>986.97</b>	<b>1411.45</b>	<b>1591.53</b>	<b>3604.03</b>	<b>4419.71</b>	<b>6172.77</b>
<b>V</b>	<b>Profit / (Loss) before exceptional item &amp; tax (III-IV)</b>	<b>133.80</b>	<b>215.67</b>	<b>208.15</b>	<b>412.65</b>	<b>858.87</b>	<b>1005.76</b>
<b>VI</b>	<b>Exceptional items</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>VII</b>	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>133.80</b>	<b>215.67</b>	<b>208.15</b>	<b>412.65</b>	<b>858.87</b>	<b>1005.76</b>
<b>VIII</b>	<b>Tax expense</b>						
	1) Current Tax	80.00	0.00	0.00	80.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	183.58	0.00	0.00	183.58	0.00	0.00
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	1.44
	<b>Total Tax Expenses</b>	<b>263.58</b>	<b>0.00</b>	<b>0.00</b>	<b>263.58</b>	<b>0.00</b>	<b>1.44</b>
<b>IX</b>	<b>Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>X</b>	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-129.78</b>	<b>215.67</b>	<b>208.15</b>	<b>149.07</b>	<b>858.87</b>	<b>1004.31</b>
<b>XI</b>	<b>Profit/(loss) from discontinued operations</b>	-3.98	(1.42)	-3.22	-9.71	-0.42	3.72
<b>XII</b>	<b>Tax expense of discontinued operations</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>XIII</b>	<b>Profit/(loss) from Discontinued operations (after tax) (XI-XII)</b>	<b>-3.98</b>	<b>(1.42)</b>	<b>(3.22)</b>	<b>-9.71</b>	<b>-0.42</b>	<b>3.72</b>
<b>XIV</b>	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XV</b>	<b>Profit/(loss) for the period (X+XIII)</b>	<b>-133.76</b>	<b>214.26</b>	<b>204.93</b>	<b>139.37</b>	<b>858.45</b>	<b>1008.03</b>
<b>XVI</b>	<b>Other comprehensive income</b>						
	(a) (i) items that will not be reclassified to statement of profit & loss	53.15	25.92	(26.86)	31.78	122.21	146.32
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Other comprehensive income :</b>	<b>53.15</b>	<b>25.92</b>	<b>(26.86)</b>	<b>31.78</b>	<b>122.21</b>	<b>146.32</b>
<b>XVII</b>	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and</b>						



	Other Comprehensive Income for the period	-80.60	240.19	178.07	171.14	980.66	1154.35
<b>XVIII</b>	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	-133.76	214.26	204.93	139.37	858.45	1008.03
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
<b>XIX</b>	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	-80.60	240.19	178.07	171.14	980.66	1154.35
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
<b>XX</b>	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
<b>XXII</b>	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	(1.04)	1.73	1.67	1.20	6.89	8.05
	b) Diluted (Rs.)	(1.04)	1.73	1.67	1.20	6.89	8.05
	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	(0.03)	(0.01)	(0.03)	(0.08)	0.00	0.03
	b) Diluted (Rs.)	(0.03)	(0.01)	(0.03)	(0.08)	0.00	0.03
	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	(1.07)	1.72	1.64	1.12	6.89	8.08
	b) Diluted (Rs.)	(1.07)	1.72	1.64	1.12	6.89	8.08

DATE: 09.02.2023  
PLACE: INDORE



For and on behalf of board of directors of  
MEDI-CAPS LIMITED

ALANKAR GARG  
MANAGING DIRECTOR  
DIN: 00274321

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**Consolidated Segmentwise Revenue, Results and Capital Employed for Quarter and Nine Months ended 31st December, 2022**

S.No.	Particulars	(Amount in Lakhs)					
		Quarter Ended			Nine Months Ended		Year Ended
		3 Month Ended 31/12/2022	3 Month Ended 30/09/2022	Corresponding 3 months ended in the previous year 31/12/2021	Year to date figures for current period ended 31/12/2022	Year to date figures for the previous year ended 31/12/2021	Previous Year ended March 31 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
<b>1</b>	<b>Segment Revenue</b>						
	Pharma Division	1,119.41	1,565.32	1,756.16	3,950.89	5,232.15	7,117.80
	Real Estate Division	1.36	61.81	43.52	65.79	46.43	60.74
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Net Sale/Income From Operations</b>	<b>1,120.77</b>	<b>1,627.13</b>	<b>1,799.68</b>	<b>4,016.68</b>	<b>5,278.58</b>	<b>7,178.53</b>
<b>2</b>	<b>Segment Results (Profit) (+)/ Loss (-) before tax and Interest</b>						
	Pharma Division	143.89	165.37	205.25	384.23	879.17	1,011.87
	Real Estate Division	(10.06)	50.31	2.92	28.58	(20.28)	(6.08)
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total</b>	<b>133.84</b>	<b>215.69</b>	<b>208.17</b>	<b>412.81</b>	<b>858.89</b>	<b>1,005.79</b>
	Interest Income	0.00	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.02	0.01	0.02	0.15	0.02	0.02
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Profit Before Tax</b>	<b>133.80</b>	<b>215.67</b>	<b>208.15</b>	<b>412.66</b>	<b>858.87</b>	<b>1,005.77</b>
<b>3</b>	<b>Capital Employed</b>						
	<b>Segment Assets (A)</b>						
	Pharma Division	12,390.31	12,727.61	12,231.75	12,390.31	12,231.75	12,861.34
	Real Estate Division	166.79	169.10	181.55	166.79	181.55	173.71
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total (A)</b>	<b>12,557.10</b>	<b>12,896.71</b>	<b>12,413.30</b>	<b>12,557.10</b>	<b>12,413.30</b>	<b>13,035.05</b>
	<b>Segment Liabilities (B)</b>						
	Pharma Division	760.36	1,019.36	961.40	760.36	961.40	1,409.45
	Real Estate Division	0.00	0.00	0.00	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total (B)</b>	<b>760.36</b>	<b>1,019.36</b>	<b>961.40</b>	<b>760.36</b>	<b>961.40</b>	<b>1,409.45</b>
<b>4</b>	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>						
	Pharma Division	11,629.95	11,708.25	11,270.35	11,629.95	11,270.35	11,451.88
	Real Estate Division	166.79	169.10	181.55	166.79	181.55	173.71
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>11,796.74</b>	<b>11,877.34</b>	<b>11,451.90</b>	<b>11,796.74</b>	<b>11,451.90</b>	<b>11,625.59</b>

DATE: 09.02.2023  
PLACE: INDORE



For and behalf of board of directors of  
MEDI-CAPS LIMITED

**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

**NOTES:**

1. The above Un-audited Financial Results for the Quarter as well as Nine Months ended December 31, 2022 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their meeting held on February 09, 2023. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This above un-audited financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Companies (Indian Accounting Standards) Rules, 2015 ("Ind-AS") prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated financial results includes the result of wholly owned subsidiary company i.e. *Medgel Private Limited*.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid Un-audited financial Results will be uploaded on the Company's website [www.medicaps.com](http://www.medicaps.com) and will also be available on the websites of the Stock exchange i.e. [www.bseindia.com](http://www.bseindia.com) for the benefit of shareholders and investors.
7. As it has been already disclosed that Company has discontinued its manufacturing activities, accordingly there is a loss from discontinue operations for the quarter and nine month ended December 31, 2022.
8. Description of Income & Expenditure of Discontinue operations

		(Amount in Lacs)		
Particulars	3 Months Ended	3 Months Ended	9 Months Ended	
	31.12.2022	30.09.2022	31.12.2022	
<b>I</b>	<b>Income from operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
II	Other Income	0.00	2.19	2.19
<b>III</b>	<b>Total income (I+II)</b>	<b>0.00</b>	<b>2.19</b>	<b>2.19</b>
IV	Expenses			
	a) Changes in Inventories of finished goods, & work in progress	0.00	0.00	0.00
	b) Employee benefits expense	0.00	0.00	0.00

	c) Finance Cost	0.00	0.00	0.00
	d) Depreciation expense	2.24	2.24	6.72
	e) Other expenses	1.74	1.37	5.18
	Total Expenses (IV)	<b>3.98</b>	<b>3.61</b>	<b>11.90</b>
<b>V</b>	<b>Net Profit/Loss From Discontinue Operation</b>	<b>-3.98</b>	<b>-1.42</b>	<b>-9.71</b>

DATE: 09/02/2023  
PLACE: INDORE

For and on behalf of the Board of Directors of  
MEDI-CAPS LIMITED



*[Handwritten signature]*

**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**